serotonin-norepinephrine reuptake inhibitor


Also found in: Medical, Wikipedia.
Related to serotonin-norepinephrine reuptake inhibitor: SSNRI

serotonin-norepinephrine reuptake inhibitor

n.
An SNRI.
References in periodicals archive ?
All participants also carried a diagnosis of major depression, depression NOS, or dysthymia for which they were taking a stable dose of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Nausea and vomiting were more common with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine (33%) than with SSRIs (22%).
The manufacturer of desvenlafaxine will conduct a 1-year study to resolve cardiovascular and hepatic safety concerns raised by the Food and Drug Administration in an "approvable" letter for the serotonin-norepinephrine reuptake inhibitor, which is under review as a treatment for menopausal hot flashes and night sweats.
SAN FRANCISCO -- The serotonin-norepinephrine reuptake inhibitor venlafaxine is as effective as paroxetine in the treatment of panic disorder, Dr.
which is developing duloxetine, a serotonin-norepinephrine reuptake inhibitor.
48 (Wellbutrin, (wellbutrin) (400 mg) (*) Wellbutrin SR) Drug Comment (+) venlafaxine Serotonin-norepinephrine reuptake inhibitor.
The manufacturer of desvenlafaxine will conduct a 1-year study aimed at resolving cardiovascular and hepatic safety concerns raised by the Food and Drug Administration in an "approvable" letter for the serotonin-norepinephrine reuptake inhibitor.
Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq[R] (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI) as a treatment for adult patients with major depressive disorder (MDD).
The 125 page report finds that the products hardest hit by generic competition will be Pfizer's anti-depressant Zoloft and Wyeth's serotonin-norepinephrine reuptake inhibitor Effexor.
The study showed the number of patients receiving a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) decreased 11.
By drug class, the global anxiety disorders and depression treatment market is segmented into selective serotonin reuptake inhibitors (SSRIs), anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), beta-blockers, atypical antipsychotics, benzodiazepines, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and tetracyclic antidepressants (TeCAs).
The report states that Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed classes of antidepressants, but many patients fail to respond adequately to them, while a significant number of patients also discontinue therapy due to negative and unwanted side effects.